RCT: Arterial chemotherapy of oxaliplatin plus fluorouracil vs. sorafenib in advanced hepatocellular carcinoma.

Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1) – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary on Twitter

FOHAIC-1 Trial: Arterial FOLFOX chemotherapy improved survival outcomes compared to sorafenib in advanced #HepatocellularCarcinoma ? https://t.co/coazeM6Tq5 #JCO #hpbcsm #LiverCancer #hccsm pic.twitter.com/QDWdSD4P7e

— Journal of Clinical Oncology (@JCO_ASCO) January 4, 2022